Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive status confers therapeutic sensitivity to Tamoxifen in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for estrogen receptor positive advanced breast cancer in pre- or post-menopausal women.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.